BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

RFVIIIFc regulatory update

FDA granted Orphan Drug designation to Swedish Orphan's rFVIIIFc to treat hemophilia A. The long-acting fully-recombinant Factor VIII Fc fusion protein is in pivotal...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >